EPHA2 and neoplasm: Later, considering the good results, the same researchers improved the treatment, generating trivalent CAR-T (tri-CAR-T) cells targeting HER2, IL-13Rα2 and ephrin type-A receptor 2 (EPHA2), which overcame the interpatient variability and could capture almost 100% of the tumor cells, showing improved results when compared with biCAR-T cells or single CAR-T cells [256].